ArticleJournal of clinical hypertension (Greenwich, Conn.)2009
Aldosterone excess or escape: Treating resistant hypertension.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2013Trial
- Effects of spironolactone on intradialytic hypertension: a multicentre, double-blind, randomized, crossover study.Clinical kidney journal · 2025Article
- Associations between Arterial Stiffness, Electrolytes, and Hormones: Insights from the LURIC Study on Cardiovascular Health.Cardiorenal medicine · 2025Article
- New Molecules for Treating Resistant Hypertension: a Clinical Perspective.Current hypertension reports · 2019Review
- Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?Current hypertension reports · 2019Review
- Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.Vascular health and risk management · 2017Review
- Should All Patients with Resistant Hypertension Receive Spironolactone?Current hypertension reports · 2016Review
- Genetics of resistant hypertension: a novel pharmacogenomics phenotype.Current hypertension reports · 2015Review
- Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension.Arquivos brasileiros de cardiologia · 2015Review
- Resistant or refractory hypertension: are they different?Current hypertension reports · 2014Review
- Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension.European journal of clinical pharmacology · 2014Article
- Hormones other than aldosterone may contribute to hypertension in 3 different subtypes of primary aldosteronism.Journal of clinical hypertension (Greenwich, Conn.) · 2013Article
- Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications.British journal of pharmacology · 2013Review
- The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients.International journal of vascular medicine · 2012Article
- Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension.Journal of human hypertension · 2011Article
- Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness.Journal of human hypertension · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aldosterone excess or "escape" can occur after treatment with medications that block the renin-angiotensin-aldosterone system or in undiagnosed primary aldosteronism. Spironolactone is thought to be an important addition to resistant hypertension (RH) treatment. In this study, resistant (RH) and controlled (CH) hypertensives and normotensive patients were submitted to echocardiography, flow-mediated vasodilation, carotid intima-media wall thickness studies, renin plasma activity, and aldosterone plasma levels and plasma and urinary sodium and potassium concentrations at baseline (pre-spironolactone phase). Subsequently, for only RH and CH groups, 25 mg/d spironolactone was added to preexisting treatments over 6 months. Afterwards, these parameters were reassessed (post-spironolactone phase). The RH and CH groups achieved reductions in blood pressure (P<.001), decreases in left ventricular hypertrophy (P<.001), improved diastolic function (Kappa index RH: 0.219 and Kappa index CH: 0.392) and increases in aldosterone concentrations (P<.05). The RH group attained improved endothelium-dependent (P<.001) and independent (P=.007) function. Optimized RH treatment with spironolactone reduces blood pressure and improves endothelial and diastolic function and left ventricular hypertrophy despite the presence of aldosterone excess or escape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.